CompletedNCT07253441
A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels
Medication studyAges 18–55United StatesADHD
Understand this study
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Lenexa and 1 more locationSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: August 29, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 174
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT07253441
- Official title
Show the full official title
A Multiple-arm, Phase 1, Open-label Trial to Determine Dose Strength Equivalence and Effect of Food on To-Be-Marketed Centanafadine QD XR Capsules, Bioequivalence Between Clinical and To-Be-Marketed QD XR Capsules and Relative Bioavailability of To-Be-Marketed QD XR Capsules to SR Tablets in Healthy Adults
Get this study by email
Recruitment & locations
CompletedLenexa · Millcreek
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including CTN XR (TBM), CTN SR and CTN XR (Clin).
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
